Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Oncology Venture Becomes Allarity Therapeutics, Announces Board, Executive Changes

Oncology Venture Becomes Allarity Therapeutics, Announces Board, Executive Changes

Sep 22, 2020
|
staff reporter

NEW YORK -- Hørsholm, Denmark-based Oncology Venture on Monday announced that it will change its name to Allarity Therapeutics, hire a new executive, and expand its board of directors as part of a long-term strategy to market the precision oncology drugs it is developing to patients in the US.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

What's Popular?

In Cancer

  1. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  2. AstraZeneca's sNDA for Tagrisso in Adjuvant, EGFR-Mutated Lung Cancer Accepted by FDA

  3. Kazia Therapeutics' Paxalisib to be Evaluated in Glioblastoma Study

  4. Baylor Study Uses Immunai Single-Cell Profiling to Analyze CAR-NKT Neuroblastoma Treatment

    Premium

  5. NGS-Based Profiling May Guide Treatment for Patients With Cancers of Unknown Primary

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.